The global diabetic nephropathy market revenue was around US$ 2.0 billion in 2022 and is estimated to reach US$ 3.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 6% during the ...

However, here’s the tricky part: as people get older, kidney function naturally slows down. This means a lower GFR might not always be a sign of disease—it could just be a part of aging. This makes it ...

Type 2 diabetes isn’t just a condition, it’s a long-term health risk that evolves silently. Timely testing, accurate readings ...

A new study published in the journal of Diabetes Research and Clinical Practice found that patients with type 1 and type 2 ...

China: A recent retrospective cohort study published in Diabetes, Metabolic Syndrome and Obesity has revealed a significant U ...

Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary ...